BIOTECH ASSISTANT / FIELD NOTES

Amphista doses first patient with DCAF16-mediated BRD9 degrader AMX-883

Company / institutional announcement · Amphista Therapeutics

Source published: 2026-10-12

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Amphista announced the first patient dose in BRAMLIE, a Phase 1 study of AMX-883 in acute myeloid leukemia and high-risk myelodysplastic syndrome. The oral candidate recruits DCAF16 to degrade BRD9. The study will evaluate safety, pharmacokinetics, and preliminary activity, moving a non-cereblon, non-VHL degradation approach beyond preclinical models and into patients.

Why it may matter

Clinical entry creates an important test for alternative E3 recruitment, while safety, tolerability, and patient benefit remain to be demonstrated.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Merck / MSD Haisco Pharmaceutical Gilead Sciences Novartis WuXi AppTec / WuXi TIDES

Explore field companies →Explore literature →

Related updates

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC Ask AI ↗

2026-11-05Evommune and Hinova / Business Wire

Evommune licenses Hinova's VAV1 molecular glue degrader outside Greater China

Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.

Protein degradation / PROTAC Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗